Piramal Enterprises Ltd - Research Report

To get a call back from your Relationship Manager, just give a missed call at +91-9773076000

Private Client Research




Pharmaceuticals & Drugs


Piramal Enterprises Ltd

Reco Price
Rs. 1047.00
Price Target (1 Year)
Rs. 1255.00


April 01, 2016
CNX Nifty




Strong Conglomerate with improved financial performance.

Formidable player in the healthcare industry:
After exiting the domestic formulation business in 2010 by selling its business to Abbott for $3.8 Bn, Piramal Enterprises Ltd. (PEL) once again strengthened its presence in the healthcare space with operations across >100 international markets including US, UK and Canada. Currently, it operates in four segments – (a) Pharma Solutions; (b) Critical Care; (c) Consumer Products; and (d) Imaging. All these pharma businesses have been growing both organically and inorganically and have demonstrated a consistent track record for growth. Also, the company is well positioned with (a) a strong contract manufacturing relationship with leading pharma companies; (b) niche products and unparalleled global footprint in the critical care segment; (c) strong brands and one of the largest India distribution networks in the consumer product segment; and (d) a game changing product in the Imaging segment.

Financial Services business:
This segment is company’s fastest growing arm of Piramal Enterprises. It has a unique collection of niche businesses and strategic investments in category leaders with a total portfolio size of Rs. 24,200 Cr (at the end of Q3FY16). It has an immense potential to grow further by increasing its leverage in

  • Wholesale lending: the company has created a niche within the Developer Financing segment with a loan book of Rs. 11,070 Cr (at end Q3FY16). It has invested in projects which have actual end user demand in Tier 1 cites – Mumbai, Pune, Bengaluru, Chennai, NCR and Ahmedabad.
  • Alternative AUM: the company currently manages 12 funds and the AUM stood at Rs. 8640 Cr in Q3Y16. The parent of Piramal group, which has a history of strong project developmental capabilities, has been of immense help in this segment. With a total investment of Rs. 4583 Cr in Shriram Group (10% stake in Shriram Transport Finance and Shriram City Union Finance each and 20% stake in Shriram Capital), the company has an exposure to retail financing segments in India
  • Used and new commercial vehicles, small and medium enterprises, consumer and gold loans: These investments provide Piramal Enterprises a strong foothold into 3000+ branches with 76000+ of manpower and a 10.5 mn customer base.

Information Management business:
Piramal provides healthcare data, analytics & insights to a large (almost all top 50 Pharma companies) and diverse set of clients which provides a high revenue visibility. The Information Management business is poised for further growth and profitability given the significant market opportunity and several organic and inorganic initiatives taken by PEL. This business segment contributes 20% to total revenue with a 24% share of the total capital employed.

Experienced Management:
The Piramal Board comprises of a blend of high profile, highly qualified and well experienced professionals. Each one of the Board members has been leading thinkers and leaders in their respective departments. The company has set a very high standard of corporate governance, which indeed is a very promising sign. All the businesses are viewed as virtual companies and have their own Business Boards/Investment Committees. It’s the high standard of corporate governance and robust review mechanism that makes PEL one of the preferred partners in India.

Stock Data

CMP (Rs)
Face value (Rs)
52 Week Range (Rs)
1067.95 - 804.00
Market cap (Rs Crores)
Price To Book Value (x)
P/E Ratio (x)

One Year indexed Stock Performance

Piramal Enterprises LtdSensex
Piramal Enterprises Ltd
Return (%)


(in %)

+91 22 6639 3000



In the US, national health expenditures increased from USD 1.4 trillion in 2000 to USD 2.6 trillion in 2010, and are expected to grow at the rate of 6% to reach USD 4.6 trillion in 2020 (Source: Centers for Medicare & Medicaid Services). Regulations such as ‘The Patient Protection and Affordable Care Act’ (PPACA) of 2010 are expected to expand coverage to 32 million uninsured individuals (Source: Congressional Budget Office). In the wake of the PPACA and the resulting higher healthcare spending trends, the primary constituents in healthcare will change the way healthcare costs are reimbursed, shifting from a focus on volume to value. This, as well as the increasing cost to bring drugs and devices to market and greater regulatory scrutiny have resulted in an increase in demand for high quality information and analytical decision support tools and need for third-party insight from experts to navigate the increasing sector and regulatory complexity.


Piramal Enterprises Limited, an Indian-based company is focused on pharmaceutical business, financial services and information management. The pharmaceutical segment includes Pharma Solutions, Critical Care, OTC and Ophthalmology, and Life Sciences. Pharma Solutions cover the entire drug-cycle, from development and manufacturing to off-patent supplies of Active Pharmaceutical Ingredients (APIs) and formulations. The Critical Care division offers inhalation anesthetics, such as Sevoflurane and Desflurane. OTC and Ophthalmology division includes products, such as Caladryl, Equal and Saridon. The Life Sciences division discovers and optimizes compounds in the areas, including Imaging, New Chemical Entity Research and Bio-orthopaedics. The financial services segment offers fund raising, deployment, monitoring and exit of real estate loans and investments services. The information management segment is a provider of syndicated research, information and analytics to the healthcare industry.

Profit & Loss Statement:- (Consolidated)
(Rs Crores)
  • Net Sales
  • Growth (%)
  • Total Expenditure
  • EBIDTA Margin (%)
  • Other Income
  • Operating Profit
  • Interest
  • PBDT
  • Depreciation
  • Profit Before Taxation & Exceptional Items
  • Exceptional Income / Expenses
  • Profit Before Tax
  • Provision for Tax
  • Profit After Tax
  • Adjusted EPS
  • 3520.19
  • -
  • 3105.38
  • 414.81
  • 11.78
  • 196.17
  • 610.98
  • 575.01
  • 35.97
  • 209.56
  • -173.59
  • -19.13
  • -192.72
  • 24.76
  • -217.48
  • -13.17
  • 4502.74
  • 27.91
  • 3867.83
  • 634.91
  • 14.10
  • 225.43
  • 860.34
  • 1049.58
  • -189.24
  • 246.90
  • -436.14
  • 1.37
  • -434.77
  • 62.75
  • -497.52
  • -29.06
  • 5122.61
  • 13.77
  • 4237.46
  • 885.15
  • 17.28
  • 254.52
  • 1139.67
  • 510.60
  • 629.07
  • 289.87
  • 339.20
  • 2696.15
  • 3035.35
  • 344.96
  • 2690.39
  • 165.17
  • 6550.00
  • 27.86
  • 5250.00
  • 1300.00
  • 19.85
  • 275.00
  • 1575.00
  • 500.00
  • 1075.00
  • 332.00
  • 743.00
  • -30.50
  • 773.50
  • 87.91
  • 685.59
  • 42.09
  • 8330.00
  • 27.18
  • 6550.00
  • 1780.00
  • 21.37
  • 275.00
  • 2055.00
  • 450.00
  • 1605.00
  • 375.00
  • 1230.00
  • 0.00
  • 1230.00
  • 139.79
  • 1090.21
  • 66.93
  • 10550.00
  • 26.65
  • 8300.00
  • 2250.00
  • 21.33
  • 275.00
  • 2525.00
  • 400.00
  • 2125.00
  • 415.00
  • 1710.00
  • 0.00
  • 1710.00
  • 194.34
  • 1515.66
  • 93.05
Source: Stockaxis Research, Company Data


The company has evolved from being a textile-centric business to a diversified conglomerate with business operations in three broad categories – healthcare, financial services and information management. All its businesses have a leadership position with significant market potential, strong revenue growth and profitability. With strong parent group and established management we see very good opportunity at current levels.

We assign valuation of 13.48x for FY2018E indicating target price of Rs 1255.



Opulent Investment Adviser Private Limited is registered as an Investment Adviser with SEBI bearing registration Number INA000002462 as per Securities and Exchange Board of India (Investment Advisers) Regulations, 2013. Opulent Investment Adviser Private Limited offer investment advisory services to clients as well as prospects.

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Opulent Investment Adviser Private Limited and its Research Analyst with reference to the subject company(s) covered in this report-:

Opulent Investment Adviser Private Limited does have any financial interest in the subject company: (NO)

Research Analyst or his/her relative’s have financial interest in the subject company: (NO)

Opulent Investment Adviser Private Limited and Research Analyst or his/her relative’s does have any material conflict of interest in the subject company: (NO)

Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: (NO)

The research Analyst has served as officer, director or employee of the subject company: (NO)

Our salespeople and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein.

This report is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person.

This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of the users of stockaxis.com / Opulent Investment Adviser Private Limited.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and we do not warrant its accuracy or completeness.

Opulent Investment Adviser Private Limited, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report.